Antibodies are indispensable for scientific discovery, but poorly validated antibodies contribute significantly to irreproducible results, wasted grant money, and lost time. Studies reveal that over 50% of commercial antibodies fail standardized validation. At GeneTex, we adhere to stringent antibody validation protocols that embrace five pillar validation (as defined by the International Working Group for Antibody Validation (IWGAV) (1)) to ensure our customers receive the highest quality antibodies.

In addition,GeneTex proudly reiterates its longstanding partnership with YCharOS, a leading open science initiative dedicated to improving reproducibility in biomedical research through rigorous antibody validation. From the outset, our scientific team has collaborated with experts in the field of antibody production to refine and optimize methodologies for antibody validation. Through its work with YCharOS,  GeneTex remains committed to providing top-quality antibodies that benefit the global biomedical community and to promoting robust and reproducible research. This collaboration is highlighted in an exciting new publication in  Nature Protocols that describes YCharOS’s work with GeneTex and other respected reagent producers (2).

 

 

Specific GeneTex recombinant antibodies that passed YCharOS’s rigorous knockout-based validation protocols

 

 

NLRP3 antibody [HL2813] GTX639954	RAB5A antibody [HL1497] GTX636971	Synaptotagmin 1 antibody [HL1626] GTX637119

 

 

Reference:

1. Nat Methods. 2016 Oct;13(10):823-7. doi: 10.1038/nmeth.3995.
2. Nat Protoc. 2024 Dec 17. Doi: 10.1038/s41596-02401095-8.